Nasdaq · CIK 0001819790
TARS Tarsus Pharmaceuticals, Inc.
Insider trading from SEC Form 4. Last filing 25 d ago. Close $73.16 on Oct 9, 2026, +30% from the 52-week low and -19% from the high.
Last 90 days
Net insider value
-$5.2M
more sold than bought
Buys
0
$0 by 0 insiders
Sells
6
$5.2M by 4 insiders
Insiders on file
11
with a Form 4 at this company
Price and insider trades, last year
TARSOct 9, 2026 · close 73.16
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Tarsus Pharmaceuticals, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 25Weak | William J Link Phd director sell | $980k 12,500 shares | -12% | - | |
| 44Moderate | Bobak R. Azamian President/CEO and Board Chair sell | $906k 10,000 shares | -1% | - | |
| 55Moderate | Elizabeth Yeu Lin Chief Medical Officer sell | $1.2M 13,953 shares | -105% | - | |
| 31Weak | Seshadri Neervannan Chief Operating Officer sell | $388k 4,564 shares | -5% | - | |
| 42Moderate | Bobak R. Azamian President/CEO and Board Chair sell | $801k 10,000 shares | -1% | - | |
| 44Moderate | Elizabeth Yeu Lin Chief Medical Officer sell | $898k 11,578 shares | -50% | - | |
| 27Weak | Seshadri Neervannan Chief Operating Officer sell | $200k 2,989 shares | -3% | +66% from low-22% from high | |
| 85Strong | Bobak R. Azamian President/CEO and Board Chair sell | $2.4M 34,603 shares | -51% | +80% from low-15% from high | |
| 52Moderate | Jeffrey S Farrow See Remarks sell | $440k 6,430 shares | -13% | +80% from low-15% from high | |
| 39Weak | Elizabeth Yeu Lin Chief Medical Officer sell | $78k 1,144 shares | -5% | +80% from low-15% from high | |
| 58Moderate | Aziz Mottiwala Chief Commercial Officer sell | $893k 13,056 shares | -18% | +80% from low-15% from high | |
| 62Notable | Seshadri Neervannan Chief Operating Officer sell | $772k 11,324 shares | -12% | +80% from low-15% from high | |
| 63Notable | Dianne C. Whitfield Chief Human Resources Officer sell | $839k 12,274 shares | -26% | +80% from low-15% from high | |
| 58Moderate | Bryan Wahl General Counsel sell | $850k 12,440 shares | -16% | +80% from low-15% from high | |
| 33Weak | William J Link Phd director sell | $860k 12,500 shares | -10% | +77% from low-16% from high | |
| 40Moderate | Seshadri Neervannan Chief Operating Officer sell | $641k 8,366 shares | -11% | +96% from low-8% from high | |
| 38Weak | Dianne C. Whitfield Chief Human Resources Officer sell | $1.3M 15,565 shares | -40% | +108% from low-2% from high | |
| 38Weak | Bobak R. Azamian President/CEO and Board Chair sell | $495k 6,000 shares | -1% | +113% from low0% from high | |
| 34Weak | Dianne C. Whitfield Chief Human Resources Officer sell | $592k 7,397 shares | -16% | +102% from low-5% from high | |
| 40Moderate | William J Link Phd director sell | $1.9M 22,946 shares | -16% | +107% from low-2% from high | |
| 26Weak | Elizabeth Yeu Lin Chief Medical Officer sell | $165k 2,078 shares | -9% | +102% from low-5% from high | |
| 20Weak | Bobak R. Azamian President/CEO and Board Chair sell | $332k 6,000 shares | -1% | +71% from low-6% from high | |
| 45Moderate | William J Link Phd director sell | $1.5M 27,116 shares | -16% | +83% from low-3% from high | |
| 19Weak | Bobak R. Azamian President/CEO and Board Chair sell | $300k 6,000 shares | -1% | +61% from low-12% from high | |
| 44Moderate | Jeffrey S Farrow See Remarks sell | $550k 13,608 shares | -27% | +27% from low-31% from high | |
| 26Weak | Elizabeth Yeu Lin Chief Medical Officer sell | $41k 1,006 shares | -12% | +33% from low-27% from high | |
| 42Moderate | Aziz Mottiwala Chief Commercial Officer sell | $766k 17,500 shares | -27% | +39% from low-24% from high | |
| 27Weak | Bobak R. Azamian President/CEO and Board Chair sell | $300k 6,000 shares | -1% | - | |
| 68Notable | Bobak R. Azamian President/CEO and Board Chair sell | $1.2M 24,216 shares | -31% | - | |
| 40Moderate | Jeffrey S Farrow See Remarks sell | $178k 3,724 shares | -14% | - |
Transactions
The last 100 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 15, 2026 | Wendy L Yarno director | MOption exercise Common Stock | +302 | - | - | 16,956 | 25 d ago |
| Sep 15, 2026 | William J Link Phd director | MOption exercise Common Stock10b5-1 | +201 | - | - | 106,987 | 25 d ago |
| Sep 15, 2026 | David E I Pyott director | MOption exercise Common Stockindirect: By the David E.I. Pyott Trust | +201 | - | - | 9,575 | 25 d ago |
| Sep 15, 2026 | Wendy L Yarno director | MOption exercise Restricted Stock Unitsderivative | -302 | $0.00 | $0 | 907 | 25 d ago |
| Sep 15, 2026 | David E I Pyott director | MOption exercise Restricted Stock Unitsderivative | -201 | $0.00 | $0 | 605 | 25 d ago |
| Sep 15, 2026 | William J Link Phd director | SOpen-market sale Common Stock10b5-1 | -11,675 | $78.33 | $915k | 95,312 | 25 d ago |
| Sep 15, 2026 | William J Link Phd director | SOpen-market sale Common Stock10b5-1 | -759 | $79.00 | $60k | 94,553 | 25 d ago |
| Sep 15, 2026 | William J Link Phd director | SOpen-market sale Common Stock10b5-1 | -66 | $80.01 | $5,281 | 94,487 | 25 d ago |
| Sep 15, 2026 | William J Link Phd director | MOption exercise Restricted Stock Unitsderivative10b5-1 | -201 | $0.00 | $0 | 605 | 25 d ago |
| Sep 4, 2026 | Elizabeth Yeu Lin Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -5,387 | $85.00 | $458k | 7,933 | 33 d ago |
| Sep 4, 2026 | Bobak R. Azamian President/CEO and Board Chair | SOpen-market sale Common Stockindirect: By the Bobak Azamian Living Trust established April 16, 201810b5-1 | -7,100 | $90.27 | $641k | 830,891 | 33 d ago |
| Sep 4, 2026 | Seshadri Neervannan Chief Operating Officer | SOpen-market sale Common Stock10b5-1 | -4,564 | $85.00 | $388k | 78,532 | 33 d ago |
| Sep 4, 2026 | Elizabeth Yeu Lin Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -5,386 | $90.00 | $485k | 2,547 | 33 d ago |
| Sep 4, 2026 | Bobak R. Azamian President/CEO and Board Chair | SOpen-market sale Common Stockindirect: By the Bobak Azamian Living Trust established April 16, 201810b5-1 | -2,900 | $91.27 | $265k | 827,991 | 33 d ago |
| Sep 4, 2026 | Elizabeth Yeu Lin Chief Medical Officer | SOpen-market sale Common Stockindirect: By Spouse's Roth IRA10b5-1 | -1,590 | $85.00 | $135k | 3,180 | 33 d ago |
| Sep 4, 2026 | Elizabeth Yeu Lin Chief Medical Officer | SOpen-market sale Common Stockindirect: By Spouse's Roth IRA10b5-1 | -1,590 | $90.00 | $143k | 1,590 | 33 d ago |
| Sep 1, 2026 | Elizabeth Yeu Lin Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -4,601 | $73.86 | $340k | 18,707 | 39 d ago |
| Sep 2, 2026 | Bobak R. Azamian President/CEO and Board Chair | SOpen-market sale Common Stockindirect: By the Bobak Azamian Living Trust established April 16, 201810b5-1 | -10,000 | $80.06 | $801k | 837,991 | 39 d ago |
| Sep 2, 2026 | Elizabeth Yeu Lin Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -5,387 | $80.00 | $431k | 13,320 | 39 d ago |
| Sep 2, 2026 | Elizabeth Yeu Lin Chief Medical Officer | SOpen-market sale Common Stockindirect: By Spouse's Roth IRA10b5-1 | -1,590 | $80.00 | $127k | 4,770 | 39 d ago |
| Mar 20, 2026 | Seshadri Neervannan Chief Operating Officer | SOpen-market sale Common Stock10b5-1 | -2,989 | $66.75 | $200k | 82,791 | Mar 24, 2026 |
| Mar 17, 2026 | Jeffrey S Farrow See Remarks | SOpen-market sale Common Stock | -2,111 | $69.42 | $147k | 47,635 | Mar 19, 2026 |
| Mar 17, 2026 | Elizabeth Yeu Lin Chief Medical Officer | SOpen-market sale Common Stock | -375 | $69.42 | $26k | 24,077 | Mar 19, 2026 |
| Mar 17, 2026 | Aziz Mottiwala Chief Commercial Officer | SOpen-market sale Common Stock | -4,286 | $69.42 | $298k | 70,250 | Mar 19, 2026 |
| Mar 17, 2026 | Bobak R. Azamian President/CEO and Board Chair | SOpen-market sale Common Stock | -10,972 | $69.42 | $762k | 57,052 | Mar 19, 2026 |
| Mar 17, 2026 | Dianne C. Whitfield Chief Human Resources Officer | SOpen-market sale Common Stock | -4,029 | $69.42 | $280k | 43,273 | Mar 19, 2026 |
| Mar 17, 2026 | Bryan Wahl General Counsel | SOpen-market sale Common Stock | -4,084 | $69.42 | $284k | 72,315 | Mar 19, 2026 |
| Mar 17, 2026 | Seshadri Neervannan Chief Operating Officer | SOpen-market sale Common Stock | -3,125 | $69.42 | $217k | 93,979 | Mar 19, 2026 |
| Mar 18, 2026 | Aziz Mottiwala Chief Commercial Officer | SOpen-market sale Common Stock | -4,330 | $68.71 | $298k | 65,920 | Mar 19, 2026 |
| Mar 18, 2026 | Dianne C. Whitfield Chief Human Resources Officer | SOpen-market sale Common Stock | -4,071 | $68.71 | $280k | 39,202 | Mar 19, 2026 |
| Mar 18, 2026 | Bryan Wahl General Counsel | SOpen-market sale Common Stock | -4,125 | $68.71 | $283k | 68,190 | Mar 19, 2026 |
| Mar 18, 2026 | Seshadri Neervannan Chief Operating Officer | SOpen-market sale Common Stock | -3,610 | $68.71 | $248k | 90,369 | Mar 19, 2026 |
| Mar 18, 2026 | Bobak R. Azamian President/CEO and Board Chair | SOpen-market sale Common Stock | -11,667 | $68.71 | $802k | 45,385 | Mar 19, 2026 |
| Mar 18, 2026 | Jeffrey S Farrow See Remarks | SOpen-market sale Common Stock | -2,133 | $68.71 | $147k | 45,502 | Mar 19, 2026 |
| Mar 18, 2026 | Elizabeth Yeu Lin Chief Medical Officer | SOpen-market sale Common Stock | -379 | $68.71 | $26k | 23,698 | Mar 19, 2026 |
| Mar 19, 2026 | Bobak R. Azamian President/CEO and Board Chair | SOpen-market sale Common Stock | -11,964 | $67.00 | $802k | 33,421 | Mar 19, 2026 |
| Mar 19, 2026 | Jeffrey S Farrow See Remarks | SOpen-market sale Common Stock | -2,186 | $67.00 | $146k | 43,316 | Mar 19, 2026 |
| Mar 19, 2026 | Elizabeth Yeu Lin Chief Medical Officer | SOpen-market sale Common Stock | -390 | $67.00 | $26k | 23,308 | Mar 19, 2026 |
| Mar 19, 2026 | Aziz Mottiwala Chief Commercial Officer | SOpen-market sale Common Stock | -4,440 | $67.00 | $297k | 61,480 | Mar 19, 2026 |
| Mar 19, 2026 | Seshadri Neervannan Chief Operating Officer | SOpen-market sale Common Stock | -4,589 | $67.00 | $307k | 85,780 | Mar 19, 2026 |
| Mar 19, 2026 | Dianne C. Whitfield Chief Human Resources Officer | SOpen-market sale Common Stock | -4,174 | $67.00 | $280k | 35,028 | Mar 19, 2026 |
| Mar 19, 2026 | Bryan Wahl General Counsel | SOpen-market sale Common Stock | -4,231 | $67.00 | $283k | 63,959 | Mar 19, 2026 |
| Mar 16, 2026 | William J Link Phd director | SOpen-market sale Common Stock10b5-1 | -3,629 | $68.09 | $247k | 125,203 | Mar 18, 2026 |
| Mar 16, 2026 | William J Link Phd director | SOpen-market sale Common Stock10b5-1 | -8,378 | $69.03 | $578k | 116,825 | Mar 18, 2026 |
| Mar 16, 2026 | William J Link Phd director | SOpen-market sale Common Stock10b5-1 | -493 | $69.75 | $34k | 116,332 | Mar 18, 2026 |
| Mar 15, 2026 | Dianne C. Whitfield Chief Human Resources Officer | MOption exercise Common Stock | +23,909 | - | - | 47,302 | Mar 17, 2026 |
| Mar 15, 2026 | Bryan Wahl General Counsel | MOption exercise Common Stock | +24,236 | - | - | 76,399 | Mar 17, 2026 |
| Mar 15, 2026 | Bobak R. Azamian President/CEO and Board Chair | MOption exercise Common Stock | +66,274 | - | - | 68,024 | Mar 17, 2026 |
| Mar 15, 2026 | Jeffrey S Farrow See Remarks | MOption exercise Common Stock | +13,042 | - | - | 49,746 | Mar 17, 2026 |
| Mar 15, 2026 | Elizabeth Yeu Lin Chief Medical Officer | MOption exercise Common Stock | +2,511 | - | - | 24,452 | Mar 17, 2026 |
| Mar 15, 2026 | Aziz Mottiwala Chief Commercial Officer | MOption exercise Common Stock | +26,482 | - | - | 74,536 | Mar 17, 2026 |
| Mar 15, 2026 | Seshadri Neervannan Chief Operating Officer | MOption exercise Common Stock | +26,287 | - | - | 97,104 | Mar 17, 2026 |
| Mar 15, 2026 | Dianne C. Whitfield Chief Human Resources Officer | MOption exercise Restricted Stock Unitsderivative | -4,463 | $0.00 | $0 | 0 | Mar 17, 2026 |
| Mar 15, 2026 | Bryan Wahl General Counsel | MOption exercise Restricted Stock Unitsderivative | -4,790 | $0.00 | $0 | 0 | Mar 17, 2026 |
| Mar 15, 2026 | Jeffrey S Farrow See Remarks | MOption exercise Restricted Stock Unitsderivative | -8,020 | $0.00 | $0 | 16,040 | Mar 17, 2026 |
| Mar 15, 2026 | Aziz Mottiwala Chief Commercial Officer | MOption exercise Restricted Stock Unitsderivative | -4,790 | $0.00 | $0 | 0 | Mar 17, 2026 |
| Mar 15, 2026 | Dianne C. Whitfield Chief Human Resources Officer | MOption exercise Restricted Stock Unitsderivative | -7,248 | $0.00 | $0 | 7,249 | Mar 17, 2026 |
| Mar 15, 2026 | Bryan Wahl General Counsel | MOption exercise Restricted Stock Unitsderivative | -7,248 | $0.00 | $0 | 7,249 | Mar 17, 2026 |
| Mar 15, 2026 | Bobak R. Azamian President/CEO and Board Chair | MOption exercise Restricted Stock Unitsderivative | -11,300 | $0.00 | $0 | 0 | Mar 17, 2026 |
| Mar 15, 2026 | Jeffrey S Farrow See Remarks | MOption exercise Restricted Stock Unitsderivative | -5,022 | $0.00 | $0 | 15,067 | Mar 17, 2026 |
| Mar 15, 2026 | Aziz Mottiwala Chief Commercial Officer | MOption exercise Restricted Stock Unitsderivative | -8,148 | $0.00 | $0 | 8,148 | Mar 17, 2026 |
| Mar 15, 2026 | Seshadri Neervannan Chief Operating Officer | MOption exercise Restricted Stock Unitsderivative | -5,097 | $0.00 | $0 | 0 | Mar 17, 2026 |
| Mar 15, 2026 | Dianne C. Whitfield Chief Human Resources Officer | MOption exercise Restricted Stock Unitsderivative | -7,176 | $0.00 | $0 | 14,351 | Mar 17, 2026 |
| Mar 15, 2026 | Bryan Wahl General Counsel | MOption exercise Restricted Stock Unitsderivative | -7,176 | $0.00 | $0 | 14,351 | Mar 17, 2026 |
| Mar 15, 2026 | Bobak R. Azamian President/CEO and Board Chair | MOption exercise Restricted Stock Unitsderivative | -16,975 | $0.00 | $0 | 16,975 | Mar 17, 2026 |
| Mar 15, 2026 | Elizabeth Yeu Lin Chief Medical Officer | MOption exercise Restricted Stock Unitsderivative | -2,511 | $0.00 | $0 | 7,534 | Mar 17, 2026 |
| Mar 15, 2026 | Aziz Mottiwala Chief Commercial Officer | MOption exercise Restricted Stock Unitsderivative | -8,020 | $0.00 | $0 | 16,040 | Mar 17, 2026 |
| Mar 15, 2026 | Seshadri Neervannan Chief Operating Officer | MOption exercise Restricted Stock Unitsderivative | -8,148 | $0.00 | $0 | 8,148 | Mar 17, 2026 |
| Mar 15, 2026 | Seshadri Neervannan Chief Operating Officer | MOption exercise Restricted Stock Unitsderivative | -8,020 | $0.00 | $0 | 16,040 | Mar 17, 2026 |
| Mar 15, 2026 | Dianne C. Whitfield Chief Human Resources Officer | MOption exercise Restricted Stock Unitsderivative | -5,022 | $0.00 | $0 | 15,067 | Mar 17, 2026 |
| Mar 15, 2026 | Bryan Wahl General Counsel | MOption exercise Restricted Stock Unitsderivative | -5,022 | $0.00 | $0 | 15,067 | Mar 17, 2026 |
| Mar 15, 2026 | Bobak R. Azamian President/CEO and Board Chair | MOption exercise Restricted Stock Unitsderivative | -23,121 | $0.00 | $0 | 46,243 | Mar 17, 2026 |
| Mar 15, 2026 | Aziz Mottiwala Chief Commercial Officer | MOption exercise Restricted Stock Unitsderivative | -5,524 | $0.00 | $0 | 16,574 | Mar 17, 2026 |
| Mar 15, 2026 | Seshadri Neervannan Chief Operating Officer | MOption exercise Restricted Stock Unitsderivative | -5,022 | $0.00 | $0 | 15,067 | Mar 17, 2026 |
| Mar 15, 2026 | Bobak R. Azamian President/CEO and Board Chair | MOption exercise Restricted Stock Unitsderivative | -14,878 | $0.00 | $0 | 44,634 | Mar 17, 2026 |
| Mar 5, 2026 | Bobak R. Azamian President/CEO and Board Chair | AGrant or award Stock Option (right to buy)derivative | +96,723 | $0.00 | $0 | 96,723 | Mar 9, 2026 |
| Mar 5, 2026 | Jeffrey S Farrow See Remarks | AGrant or award Stock Option (right to buy)derivative | +30,724 | $0.00 | $0 | 30,724 | Mar 9, 2026 |
| Mar 5, 2026 | Elizabeth Yeu Lin Chief Medical Officer | AGrant or award Stock Option (right to buy)derivative | +27,310 | $0.00 | $0 | 27,310 | Mar 9, 2026 |
| Mar 5, 2026 | Aziz Mottiwala Chief Commercial Officer | AGrant or award Stock Option (right to buy)derivative | +30,724 | $0.00 | $0 | 30,724 | Mar 9, 2026 |
| Mar 5, 2026 | Seshadri Neervannan Chief Operating Officer | AGrant or award Stock Option (right to buy)derivative | +27,310 | $0.00 | $0 | 27,310 | Mar 9, 2026 |
| Mar 5, 2026 | Dianne C. Whitfield Chief Human Resources Officer | AGrant or award Stock Option (right to buy)derivative | +27,310 | $0.00 | $0 | 27,310 | Mar 9, 2026 |
| Mar 5, 2026 | Bryan Wahl General Counsel | AGrant or award Stock Option (right to buy)derivative | +27,310 | $0.00 | $0 | 27,310 | Mar 9, 2026 |
| Mar 5, 2026 | Bobak R. Azamian President/CEO and Board Chair | AGrant or award Restricted Stock Unitsderivative | +60,776 | $0.00 | $0 | 60,776 | Mar 9, 2026 |
| Mar 5, 2026 | Jeffrey S Farrow See Remarks | AGrant or award Restricted Stock Unitsderivative | +19,306 | $0.00 | $0 | 19,306 | Mar 9, 2026 |
| Mar 5, 2026 | Elizabeth Yeu Lin Chief Medical Officer | AGrant or award Restricted Stock Unitsderivative | +17,161 | $0.00 | $0 | 17,161 | Mar 9, 2026 |
| Mar 5, 2026 | Aziz Mottiwala Chief Commercial Officer | AGrant or award Restricted Stock Unitsderivative | +19,306 | $0.00 | $0 | 19,306 | Mar 9, 2026 |
| Mar 5, 2026 | Seshadri Neervannan Chief Operating Officer | AGrant or award Restricted Stock Unitsderivative | +17,161 | $0.00 | $0 | 17,161 | Mar 9, 2026 |
| Mar 5, 2026 | Dianne C. Whitfield Chief Human Resources Officer | AGrant or award Restricted Stock Unitsderivative | +17,161 | $0.00 | $0 | 17,161 | Mar 9, 2026 |
| Mar 5, 2026 | Bryan Wahl General Counsel | AGrant or award Restricted Stock Unitsderivative | +17,161 | $0.00 | $0 | 17,161 | Mar 9, 2026 |
| Mar 4, 2026 | Seshadri Neervannan Chief Operating Officer | SOpen-market sale Common Stock10b5-1 | -8,366 | $76.67 | $641k | 70,817 | Mar 5, 2026 |
| Feb 18, 2026 | David E I Pyott director | AGrant or award Stock Option (right to buy)derivative | +5,893 | $0.00 | $0 | 5,893 | Feb 20, 2026 |
| Feb 18, 2026 | David E I Pyott director | AGrant or award Restricted Stock Unitsderivative | +3,729 | $0.00 | $0 | 3,729 | Feb 20, 2026 |
| Dec 15, 2025 | Katherine Goodrich director | MOption exercise Common Stock | +2,233 | - | - | 2,233 | Jan 14, 2026 |
| Dec 15, 2025 | Katherine Goodrich director | MOption exercise Restricted Stock Unitsderivative | -2,233 | $0.00 | $0 | 4,467 | Jan 14, 2026 |
| Jan 2, 2026 | Dianne C. Whitfield Chief Human Resources Officer | SOpen-market sale Common Stock10b5-1 | -5,715 | $80.09 | $458k | 33,243 | Jan 6, 2026 |
| Jan 2, 2026 | Dianne C. Whitfield Chief Human Resources Officer | SOpen-market sale Common Stock10b5-1 | -8,122 | $80.71 | $656k | 25,121 | Jan 6, 2026 |
| Jan 2, 2026 | Dianne C. Whitfield Chief Human Resources Officer | SOpen-market sale Common Stock10b5-1 | -835 | $81.90 | $68k | 24,286 | Jan 6, 2026 |
| Jan 2, 2026 | Dianne C. Whitfield Chief Human Resources Officer | SOpen-market sale Common Stock10b5-1 | -893 | $82.93 | $74k | 23,393 | Jan 6, 2026 |
| Dec 24, 2025 | Bobak R. Azamian President/CEO and Board Chair | SOpen-market sale Common Stockindirect: By the Bobak Azamian Living Trust established April 16, 201810b5-1 | -5,443 | $82.41 | $449k | 858,548 | Dec 30, 2025 |
| Dec 24, 2025 | Bobak R. Azamian President/CEO and Board Chair | SOpen-market sale Common Stockindirect: By the Bobak Azamian Living Trust established April 16, 201810b5-1 | -557 | $83.54 | $47k | 857,991 | Dec 30, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Bobak R. AzamianPresident/CEO and Board Chair
- Jeffrey S FarrowSee Remarks
- Katherine Goodrichdirector
- William J Link Phddirector
- Elizabeth Yeu LinChief Medical Officer
- Aziz MottiwalaChief Commercial Officer
- Seshadri NeervannanChief Operating Officer
- David E I Pyottdirector
- Bryan WahlGeneral Counsel
- Dianne C. WhitfieldChief Human Resources Officer
- Wendy L Yarnodirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.